Clinical Decision Support Systems Revolutionize the EMR to Become the Leader for Patient Empowerment

SANTA CLARA, Calif., Aug. 20, 2019 /PRNewswire/ — Clinical decision support systems (CDSS) are poised to become the user interface of choice for clinical interactions with health IT, ultimately supplanting the electronic health record (EHR) system as the primary health IT point of interface for clinicians. As decision support becomes a critical component of both healthcare delivery as well as regulatory compliance, the market is forecast to grow from $3.79 billion in 2018 to $6.4 billion in 2024, at a compound annual growth rate (CAGR) of 9.3%.

“With the delivery of healthcare becoming more complex, there is an urgent need for a superior user interface, both to reduce the load on the physician, as well as ensure that the physician is informed of the latest treatment options and protocols,” said Mike Jude, Research Manager, Digital Health. “The trend towards more regulatory oversight and the adoption of new information technology will further drive the need for CDS.”

Frost & Sullivan’s recent analysis, US Clinical Decision Support Systems Market, Forecast to 2024, analyzes the latest trends impacting the CDSS space. It forecasts market growth in clinical knowledge and medical evidence, healthcare analytics, workflow solutions, EHRs, medical devices, data support, clinical surveillance, and CDS platforms. It also studies the impact of changes in regulation and technologies on the market outlook.

For further information on this analysis, please visit: http://frost.ly/3p4.

“CDSS has been heavily impacted by the Health Information Technology for Economic and Clinical Health (HITECH) and, more recently, the Health and Human Services (HHS) requirements for interoperability and patient empowerment,” noted Jude. “These regulatory requirements encourage EHRs and electronic medical records (EMRs) vendors to either include CDS data within the properties of the electronic record or offer ways for users to link-out to CDS sources or workflow capabilities.”

Over the forecast period, CDSS is expected to find substantial adoption in the area of patient surveillance and as an essential interface between EHR complexity and the clinical workflow. There are other significant growth opportunities in:

  • Making systems interoperable; hospital administrators should push aggressively for this to happen.
  • Extending services to cover population health to improve patient outcomes and augment the role of clinical data in driving success.
  • Studying results of in-place clinical surveillance systems and evaluating the potential to create measurable value propositions.
  • Using automation to communicate directly with the patient and EHR for important, but not critical, actions.
  • Ensuring that patient portals or text-based systems are optimized according to the need of the patients.

US Clinical Decision Support Systems Market, Forecast to 2024 is part of Frost & Sullivan’s global Digital Health Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

US Clinical Decision Support Systems Market, Forecast to 2024
K360-48

Contact:
Mariana Fernandez
T: +1 210 348 10 12
T: +54 11 4778 3540
E: Mariana.Fernandez@frost.com

http://ww2.frost.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/clinical-decision-support-systems-revolutionize-the-emr-to-become-the-leader-for-patient-empowerment-300904386.html

SOURCE Frost & Sullivan

Staff

Recent Posts

CorVel Announces Effectiveness of Three-For-One Forward Stock Split

FORT WORTH, Texas, Dec. 24, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced…

5 hours ago

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be…

5 hours ago

Best Testosterone Supplement For Men Over 40 and 50: Testo Prime for Muscle Growth & Libido 2025

If you are male and in your 40's and 50's and feel your testosterone levels…

17 hours ago

The Anxiety Clinic Launches Innovative Approach to Transform Anxiety into Positive Energy

Transforming Anxiety into Positive Energy: A New Approach by The Anxiety ClinicBondi Junction, New South…

21 hours ago

Solace Psychology Announces Expanded Holiday Stress Management and Mental Health Support Services

Embracing Mental Well-Being During the Festive SeasonCarlton North, Australia--(Newsfile Corp. - December 24, 2024) -…

23 hours ago

Strong Natural Diet Pill Over the Counter for 2025 – PhenQ OTC Weight Loss Supplement

If you are researching the strongest over the counter weight loss supplements in 2025 -…

23 hours ago